A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatments

Launched by DAIICHI SANKYO · Sep 25, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how Chinese patients with advanced non-small cell lung cancer (NSCLC) respond to treatments after they have already received at least two different therapies. Researchers will look back at medical records to gather information about the treatments these patients received, the outcomes of those treatments, and how often certain genetic changes are found in their tumors. The goal is to learn more about treatment patterns and the effectiveness of different therapies for patients with or without specific genetic alterations.

To be eligible for this study, participants must be at least 18 years old and have a confirmed diagnosis of advanced stage IV NSCLC. They should have received second or third-line treatments between September 2019 and December 2022, with specific requirements depending on whether their cancer has certain genetic features. Participants will not be able to join if they have taken part in other lung cancer trials during the study period or have other types of cancer. The study is currently active but not recruiting new participants, meaning that researchers are collecting data from existing medical records rather than enrolling new patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Participants aged ≥18 years when diagnosed with advanced NSCLC.
• • 2. Histologically or cytologically confirmed stage IV NSCLC.
• • 3. For non-AGA participants , second- or third-line systemic treatment occurred between September 1, 2019 and December 31, 2022, and participants received corresponding immunotherapy in the first or second line.
• • 4. For AGA participants , second- or third-line systemic treatment occurred between September 1, 2019 and December 31, 2022. Among them, participants with documented positive result for EGFR, ALK, or ROS1 testing received corresponding targeted therapy in the first or second line.
• Exclusion Criteria:
• • This study excludes participants who met any of the following criteria.
• • 1. Having records of participation or past participation in clinical trial for lung cancer within the data collection period of the study.
• • 2. Participants with a concomitant cancer at the time of diagnosis of NSCLC (except for non-metastatic non-melanoma skin cancers, in situ or benign neoplasms). Occurrence of cancer within 5 years after NSCLC diagnosis will be considered as secondary cancer.
• • 3. Histology of the tumor is small cell lung cancer, neuroendocrine in origin, or a mixed histologic type with small cell and non-small cell lung cancers.
• • 4. Participants with significantly missing medical record data or patients deemed inappropriate for inclusion by investigators.